Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.

Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao3003. doi: 10.1126/scitranslmed.aao3003.

PMID:
29643228
2.

Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia.

Darbinyan K, Shastri A, Budhathoki A, Helbig D, Snyder R, Pradhan K, Saleh-Esa J, Kornblum NS, Binder AF, Goel S, Janakiram M, Derman O, Gritsman K, Steidl U, Braunschweig I, Verma A, Mantzaris I.

Blood Adv. 2017 Oct 26;1(24):2120-2123. doi: 10.1182/bloodadvances.2017007013. eCollection 2017 Nov 14.

3.

Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma.

Shastri A, Janakiram M, Mantzaris I, Yu Y, Londono JS, Verma AK, Barta SK.

Oncotarget. 2017 Jul 14;8(45):78410-78418. doi: 10.18632/oncotarget.19240. eCollection 2017 Oct 3.

4.

Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U.

J Clin Invest. 2017 Dec 1;127(12):4297-4313. doi: 10.1172/JCI92504. Epub 2017 Oct 30.

5.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

PMID:
28684528
6.

Adult T-cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy.

Zell M, Assal A, Derman O, Kornblum N, Battini R, Wang Y, Narasimhulu DM, Mantzaris I, Shastri A, Verma A, Ye H, Braunschweig I, Janakiram M.

Oncotarget. 2016 Aug 9;7(32):51981-51990. doi: 10.18632/oncotarget.10223.

7.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A.

Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10.

8.

Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans.

Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK.

Oncotarget. 2016 Oct 18;7(42):67948-67955. doi: 10.18632/oncotarget.8996.

9.

High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.

Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A.

Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. No abstract available.

PMID:
27125205
10.

Analysis of chronic myelogenous leukemia in an underserved, inner-city cohort shows a significant five year overall survival that is not affected by choice of tyrosine kinase inhibitor.

Assal A, Dong B, Khan H, Medavarapu R, Shastri A, Pradhan K, Friedman E, Mantzaris I, Janakiram M, Battini R, Kornblum N, Yu Y, Verma A, Braunschweig I, Derman O.

Leuk Lymphoma. 2016 Oct;57(10):2452-5. doi: 10.3109/10428194.2016.1142087. Epub 2016 Feb 17. No abstract available.

PMID:
26886689
11.

Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity.

Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A.

Haematologica. 2014 May;99(5):930-6. doi: 10.3324/haematol.2013.101949. Epub 2014 Feb 7.

12.

Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A.

J Hematol Oncol. 2013 Jul 10;6:50. doi: 10.1186/1756-8722-6-50. Review.

13.

miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.

Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A.

Blood. 2013 Apr 11;121(15):2875-81. doi: 10.1182/blood-2011-12-397067. Epub 2013 Feb 6.

14.

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A.

Cancer Res. 2011 Feb 1;71(3):955-63. doi: 10.1158/0008-5472.CAN-10-2933. Epub 2010 Dec 28. Erratum in: Cancer Res. 2011 Apr 1;71(7):2806. Mantzaris, Giannis [corrected to Mantzaris, Ioannis].

15.

Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.

Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, Fragos I, Rigatos G.

Anticancer Res. 2008 Sep-Oct;28(5B):3087-92.

16.

Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity.

Ardavanis A, Koumna S, Fragos I, Malliou S, Kyriakou F, Mantzaris I, Scorilas A, Rigatos G.

Anticancer Res. 2008 Jul-Aug;28(4C):2409-15.

17.

Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.

Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G.

Oncologist. 2008 Apr;13(4):361-9. doi: 10.1634/theoncologist.2007-0207.

18.

Urachal mucinous adenocarcinoma: a case report.

Kountourakis P, Ardavanis A, Mantzaris I, Mitsaka D, Rigatos G.

J BUON. 2007 Oct-Dec;12(4):547-8.

PMID:
18067216

Supplemental Content

Loading ...
Support Center